Oncology imaging suite with deep learning receives FDA clearance

20th February 2018
Source: Arterys
Posted By : Enaie Azambuja
Oncology imaging suite with deep learning receives FDA clearance

Arterys Inc. has announced its fifth 510(k) clearance from the FDA. The clearance is for the Arterys Oncology AI suite, and is a milestone indicative of the company's momentum in applying AI to advance medical imaging accuracy and consistency. The new oncology software complements Arterys' existing web-based offering, and helps clinicians measure and track tumors or potential cancers, and easily apply radiological standards.

The initial deep learning workflows will be for liver MRI and CT scans as well as for lung CT scans. With this new technology, radiologists can now easily confirm, evaluate, quantify, and report on the absence or presence of lung nodules and liver lesions along with their key characteristics using a simple web browser. The company plans additional deep learning workflows for solid tumours in other organs.

"The evaluation of primary and metastatic disease in the lung and liver are among the most valuable contributions of radiologists to the care of patients with cancer," said radiologist and Arterys co-founder Albert Hsiao, M.D., Ph.D.

"We desperately need more efficient technology to automatically track lung and liver lesions to further improve diagnosis, assess response to treatment, and automate reporting with standardised terminology including Lung-RADS and LI-RADS. The Oncology Lung AI and Liver AI products are designed to maximise efficiency and accuracy of the radiologist read and will power next-generation radiology interpretation."

Oncology AI runs on the Arterys MICA (Medical Imaging Cloud AI) platform, which is easier to deploy than on-premise imaging systems and complies with patient data privacy and security requirements in 27 countries, including the US, Canada, all of Europe, Australia, and New Zealand.

The software uses deep learning to automate the segmentation of lung nodules and liver lesions, with accuracy equal to segmentations performed manually by experienced clinicians. The clinician has the capability to edit these automated segmentations, so they always remain in control.

"Cancer is one of the leading causes of morbidity and mortality worldwide, with about 14 million new cases in 2012, and about 8.8 million deaths in 2015, according to the World Health Organisation," said Arterys CEO Fabien Beckers, Ph.D.

"A core Arterys mission is to help the medical community identify cancer earlier, so that patients can receive optimal treatment and improved prognosis. FDA clearance of our Oncology AI suite will help clinicians to quickly measure and track tumours over time. Additionally, our software enables seamless collaboration for clinicians, so second opinions can be easily gathered from within the hospital, or from outside experts."


You must be logged in to comment

Write a comment

No comments




Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

CES 2019
8th January 2019
United States of America Las Vegas, Nevada
Southern Manufacturing & Electronics 2019
5th February 2019
United Kingdom Farnborough
embedded world 2019
26th February 2019
Germany Nuremberg
Wearable Tech Show 2019
12th March 2019
United Kingdom London
AMPER 2019
19th March 2019
Czech Republic Brno Exhibition Centre